Journal of Cancer Research and Immuno-Oncology

OPEN ACCESS Freely available online

Commentary

# Liquid Biopsy Biomarkers Supporting Early Cancer Detection and Therapeutic Monitoring

**Adrian Kessler***

*Department of Clinical Cancer Diagnostics, Alpine Institute of Biomedical Innovation, Innsbruck, Austria*

## DESCRIPTION

Cancer diagnosis has traditionally relied upon tissue biopsy followed by microscopic examination, molecular characterization, and clinical staging to determine disease type and guide therapeutic decisions. Although tissue analysis remains indispensable for establishing pathological diagnosis, repeated collection of biopsy specimens is often limited by procedural risks, anatomical accessibility, patient discomfort, and sampling variability. Furthermore, individual malignant lesions frequently display considerable biological diversity, meaning that a single tissue specimen may not fully represent the molecular characteristics of the entire disease. These limitations have encouraged the development of complementary diagnostic approaches capable of providing continuous information regarding disease evolution through minimally invasive procedures. Among these approaches, liquid biopsy has become an important area within cancer research and immuno-oncology because it enables evaluation of circulating biomarkers released by malignant and stromal cells into body fluids. Continuous improvements in molecular technologies have expanded the clinical relevance of liquid biopsy while improving understanding of disease progression, therapeutic responsiveness, and biological heterogeneity.

Liquid biopsy refers to analysis of biological material obtained from body fluids such as blood, urine, cerebrospinal fluid, pleural fluid, saliva, or other accessible clinical specimens. Unlike conventional tissue biopsy, liquid biopsy provides opportunities for repeated sampling throughout disease management without requiring invasive surgical procedures. Multiple categories of circulating biomarkers can be evaluated simultaneously, including circulating tumor cells, cell-free nucleic acids, extracellular vesicles, proteins, metabolites, cytokines, and additional molecular components released from malignant tissues. Together, these biomarkers provide valuable information regarding disease biology and temporal changes occurring during treatment.

Circulating tumor cells represent one of the earliest liquid biopsy biomarkers investigated in clinical oncology. These intact malignant cells detach from primary lesions or metastatic sites before entering the bloodstream. Although circulating tumor cells occur in relatively low numbers, technological advances now permit their isolation and molecular characterization using highly sensitive analytical methods. Examination of these cells provides insight into cellular morphology, transcriptional activity, protein expression, chromosomal alterations, and metabolic characteristics. Their molecular diversity reflects biological heterogeneity present within malignant disease and contributes to understanding mechanisms associated with dissemination and therapeutic responsiveness.

Proteomic analysis represents another expanding area within liquid biopsy research. Proteins released into circulation reflect ongoing biological processes associated with malignant transformation, extracellular matrix remodeling, angiogenesis, metabolism, inflammatory activity, and tissue injury. High-throughput analytical technologies permit simultaneous measurement of hundreds of circulating proteins, generating molecular signatures associated with disease stage and therapeutic responsiveness. Integration of proteomic findings with genomic and transcriptomic information strengthens comprehensive characterization of cancer biology.

Metabolomics complements genomic and proteomic investigations by examining low-molecular-weight compounds circulating within body fluids. Glucose metabolites, amino acid derivatives, lipids, nucleotides, organic acids, and numerous additional molecules reflect metabolic adaptation occurring within malignant tissues and surrounding stromal populations. Alterations in circulating metabolite profiles provide insight into changes affecting energy production, mitochondrial activity, oxidative balance, and communication among diverse cellular populations. Such metabolic information contributes to a broader understanding of disease physiology.

Macrophages and dendritic cells release cytokines, chemokines, extracellular vesicles, and additional signaling molecules detectable through liquid biopsy technologies. These biomarkers reflect ongoing communication among inflammatory populations, stromal cells, and malignant tissues. Longitudinal

**Correspondence to:** Adrian Kessler, Department of Clinical Cancer Diagnostics, Alpine Institute of Biomedical Innovation, Innsbruck, Austria, E-mail : adrian.kessler@aibi-austria.edu

**Received:** 01-Jun-2026, Manuscript No. JCRIO-26-43989; **Editor assigned:** 03-Jun-2026, PreQC No. JCRIO-26-43989(PQ); **Reviewed:** 17-Jun-2026, QC No. JCRIO-26-43989; **Revised:** 24-Jun-2026, Manuscript No. JCRIO-26-43989 (R); **Published:** 01-Jul-2026, DOI: 10.35248/2684-1266.26.12.289

**Citation:** Kessler A (2026). Liquid Biopsy Biomarkers Supporting Early Cancer Detection and Therapeutic Monitoring. J Cancer Res Immunooncol. 11:289.

**Copyright:** © 2026 Kessler A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

evaluation of inflammatory biomarkers assists investigation of biological responses occurring throughout therapeutic intervention while improving understanding of disease-associated inflammatory regulation.

Recent advances in sequencing technologies have substantially increased the analytical sensitivity of liquid biopsy investigations. Digital polymerase chain reaction, next-generation sequencing, methylation analysis, and fragmentomic profiling permit detection of extremely low concentrations of circulating molecular material. These technological improvements enable identification of subtle biological changes occurring during early disease development and therapeutic intervention.

Single-cell technologies further strengthen liquid biopsy research by permitting molecular characterization of individual circulating tumor cells isolated from peripheral blood. Rather than examining mixed cellular populations, investigators can determine transcriptional activity, protein expression, chromosomal alterations, and metabolic characteristics within individual cells. These analyses reveal remarkable biological diversity among circulating malignant populations while contributing to understanding of disease dissemination.

The intestinal microbiome has recently gained attention as a potential contributor to circulating biomarker profiles. Microbial metabolites, extracellular vesicles, and regulatory molecules generated within the gastrointestinal tract enter systemic circulation and influence host metabolism, inflammatory regulation, and communication among stromal populations. Integration of microbiome research with liquid biopsy technologies represents an expanding field investigating interactions between microbial ecology and malignant disease.

Serial liquid biopsy sampling provides valuable opportunities for monitoring disease evolution over time. Unlike tissue biopsy, which often represents a single clinical time point, repeated blood collection permits continuous evaluation of molecular alterations occurring during therapy. Dynamic changes in circulating biomarkers may precede radiological findings, allowing earlier recognition of biological responses associated with treatment effectiveness or disease recurrence.

## CONCLUSION

Future progress in cancer research and immuno-oncology will continue to strengthen the role of liquid biopsy as a complementary diagnostic and monitoring strategy. Integration of circulating tumor cells, cell-free nucleic acids, extracellular vesicles, proteins, metabolites, inflammatory mediators, and computational analysis provides comprehensive insight into disease biology while reducing dependence on repeated invasive tissue sampling. Continued advances in molecular technologies, artificial intelligence, single-cell analysis, and biomarker validation are expected to improve diagnostic precision, therapeutic monitoring, individualized patient assessment, and long-term clinical management across a broad spectrum of human malignancies.